The Last Mile: Collaborating to Keep Micromobility Rolling in 2021

Like most markets, the first half of 2020 proved a bumpy ride for the micromobility sector. But through resiliency and collaboration, many industry players closed out the year fielding more demand than ever for sustainable and sharable vehicle systems. Across hardware and software, working together will pave the road for a successful 2021. In this podcast, Tony Ho, VP of Global Business Development for Segway, and Vince Cifani, CEO and Founder of micromobility SaaS platform Joyride, speak about the impact COVID-19 had on the industry, and how their companies’ collaborative efforts will ultimately improve micromoiblity for end-users.

In the US, the pandemic found its roots in March of 2020, but Ho says Segway felt the concerns right from the start of the year due to China’s supply chain relationships. “We were very worried about a supply shock,” Ho says. “That turned into a demand shock instead.” The supply chain eventually returned to normal levels, but Ho notes that lockdowns in various areas affected people’s ability to go places, making micromobility transportation options attractive alternatives to public transit. “On the second half of 2020, we saw a lot of crazy demand for our scooters and other form factors as well.”

Cifani recognizes the challenges brought on by the pandemic but says the most significant industry obstacles for scooter-sharing operators actually existed pre-pandemic: Affordable insurance for fleets, vehicle selection and fulfillment, and how to maintain and operate their fleets properly. “Through collaboration with industry leaders like Segway, we’re resolving these challenges for businesses that operate on our software platform,” Cifani says.

Ho and Cifani believe 2021 will be an important year for collaboration in the micromobility industry, both from a technology level and an intercompany. Ho says companies within the industry are more specialized now and that requires collaboration between other specialized companies. “People see the need to focus, but at the same time, they see the need to efficiently work together,” Ho says.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More